Entries by Phil Case

AnPac Bio Reports Fiscal Year 2021 Annual Financial Results

AnPac Bio Reports Fiscal Year 2021 Annual Financial Results Philadelphia, PA, May 16, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its annual financial results for the year ended December 31, 2021. Financial Highlights for […]

AnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capital Market

AnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capital Market Philadelphia, PA, May 11, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that The […]

Nasdaq Hearing Panel Grants AnPac Bio’s Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Capital Market

Nasdaq Hearing Panel Grants AnPac Bio’s Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Capital Market Philadelphia, PA, May 6, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and […]

AnPac Bio and New Investor Sign Equity Investment Totaling $15 Million

AnPac Bio and New Investor Sign Equity Investment Totaling $15 Million Philadelphia, PA, April 11, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on April 4, 2022, the Company and […]

AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late April

AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late April Philadelphia, PA, April 4, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening […]

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; In-tends to Request Hearing

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing Philadelphia, PA, March 25, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on March 24, […]

AnPac Bio-Medical Sciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

AnPac Bio-Medical Sciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement Philadelphia, PA, March 11, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that on March 8, […]

AnPac Bio’s Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic Alternatives

AnPac Bio’s Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic Alternatives Philadelphia, PA, March 2, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening […]

AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA Philadelphia, PA, February 3, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that it has […]

©2021 Anpac Bio-Medical Science Co., Ltd.